Scinai Immunotherapeutics Extends Acquisition Timeline and Seeks €12M European Grant for Autoimmune Disease Treatment

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) has executed a Second Amendment to its Binding Option Agreement for the acquisition of PinCell S.r.l. and submitted a revised application under the European Funds for the Modern Economy SMART Path program. The updated application seeks €12 million in non-dilutive, non-repayable funding to support a €15 million integrated research and development program for PC111, representing 80% co-financing. This financial support is crucial for advancing PC111, a fully human monoclonal antibody targeting soluble Fas Ligand for the treatment of pemphigus vulgaris and Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis, toward early clinical development and human proof of concept.

The amendment extends the option condition deadline to August 31, 2026, and the exercise period to September 30, 2026, aligning with the anticipated three- to four-month grant review timeline. This strategic timing allows Scinai to potentially secure substantial non-dilutive funding before committing to the full acquisition of PinCell, minimizing financial risk while maximizing development opportunities for their autoimmune disease treatment pipeline. The company's newsroom provides additional information about their ongoing developments at https://ibn.fm/SCNI.

PC111 represents a significant advancement in treating severe autoimmune skin conditions that currently have limited therapeutic options. Pemphigus vulgaris is a rare autoimmune blistering disease affecting the skin and mucous membranes, while Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis are life-threatening skin reactions often triggered by medications. The €12 million grant application under the SMART Path program demonstrates the European Union's recognition of the medical need for innovative treatments in this therapeutic area and Scinai's positioning to address this unmet need.

The financial implications of this announcement are substantial for Scinai shareholders and potential investors. Non-dilutive funding of this magnitude would allow the company to advance PC111 through critical development milestones without issuing additional shares that would dilute existing ownership. The extended option agreement timeline provides strategic flexibility, enabling Scinai to align its acquisition decision with grant funding outcomes and clinical development progress. This coordinated approach to financing and corporate development reflects sophisticated biopharmaceutical strategy execution during a challenging capital market environment for emerging biotechnology companies.

The broader implications extend to the autoimmune disease treatment landscape, where new therapeutic approaches are urgently needed. Successful development of PC111 could establish a new treatment paradigm for conditions characterized by excessive Fas Ligand activity, potentially benefiting patients who currently face limited options and poor outcomes. The company's progress can be followed through their official communications channels, with the full press release available at https://ibn.fm/NmtDv for those seeking detailed information about these developments.